Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06840003 (EOS200271) 是口服具有活力的、选择性的IDO-1抑制剂,抑制 hIDO-1, dIDO-1和 mIDO-1 的IC50分别为 0.41 μM, 0.59 μM,和 1.5 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 243 | 现货 | ||
2 mg | ¥ 346 | 现货 | ||
5 mg | ¥ 562 | 现货 | ||
10 mg | ¥ 892 | 现货 | ||
25 mg | ¥ 1,690 | 现货 | ||
50 mg | ¥ 2,730 | 现货 | ||
100 mg | ¥ 4,380 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 619 | 现货 |
产品描述 | PF-06840003 (EOS200271) is a specific and oral active IDO-1 inhibitor. |
靶点活性 | IDO1 (human):0.41 μM, IDO1 (mouse):1.5 μM, dIDO1:0.59 μM |
体外活性 | The s of PF-06840003 has inhibitory for hIDO-1 (IC50: 0.41 μM), mouse IDO-1 (IC50: 1.5 μM) and dog IDO-1 (IC50: 0.59 μM), respectively. It has very weak inhibitory against hTDO-2 (IC50: 140 μM). In cellular assays, PF-06840003 shows activity both in the LPS/INFγ-stimulated THP1 cells (IC50: 1.7 μM) and in the HeLa assay (IC50: 1.8 μM). PF-06840003 is a very weak inhibitory against CYPs (IC50>100 μM) except 2C19 (IC50: 78 μM). |
体内活性 | In mice, PF-06840003 reduces intratumoral kynurenine levels (>80%). In multiple preClinicalal syngeneic models in mice, It inhibits tumor growth by combinated with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours. |
别名 | EOS200271, PF 06840003 |
分子量 | 232.21 |
分子式 | C12H9FN2O2 |
CAS No. | 198474-05-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (258.39 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.3064 mL | 21.5322 mL | 43.0645 mL | 107.6612 mL |
5 mM | 0.8613 mL | 4.3064 mL | 8.6129 mL | 21.5322 mL | |
10 mM | 0.4306 mL | 2.1532 mL | 4.3064 mL | 10.7661 mL | |
20 mM | 0.2153 mL | 1.0766 mL | 2.1532 mL | 5.3831 mL | |
50 mM | 0.0861 mL | 0.4306 mL | 0.8613 mL | 2.1532 mL | |
100 mM | 0.0431 mL | 0.2153 mL | 0.4306 mL | 1.0766 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-06840003 198474-05-4 Metabolism IDO Indoleamine 2,3-Dioxygenase (IDO) EOS-200271 EOS200271 PF 06840003 inhibit Inhibitor PF06840003 EOS 200271 inhibitor